Oral Oncology 92 (2019) 57–58

Contents lists available at ScienceDirect

Oral Oncology

journal homepage: www.elsevier.com/locate/oraloncology

Perspectives

Potentially premalignant disorder/lesion versus potentially premalignant patient: Relevance in clinical care

Betul Ilhan[a,*], Joel B. Epstein[b,c], Pelin Guneri[a]

[a] Ege University, School of Dentistry, Department of Oral and Maxillofacial Radiology, Bornova 35100, Izmir, Turkey
[b] Samuel Oschin Comprehensive Cancers Institute, Cedars-Sinai Health System, Los Angeles, CA 90048, United States
[c] Division of Otolaryngology and Head and Neck Surgery City of Hope, 1500 East Duarte Road, Duarte, CA 91010, United States

ARTICLE INFO

Keywords:
Oral mucosa
Oral premalignant conditions
Malignancy
Oral carcinogenesis

ABSTRACT

This communication presents a discussion of patient risk factors and outcomes for potentially malignant and malignant lesions in contrast to lesion assessment and lesion management. The shift in consideration may have implications for research and clinical intervention. This compact review discusses several local and systemic components that contribute to the development of malignant changes and discusses whether patients instead of lesions should be defined as having a potentially premalignant condition.

Introduction

Carcinogenesis is conceptualized as multistep process through the continuum from normal epithelium to invasive carcinoma [1,2]. Within this continuum, oral epithelial dysplasia is considered as a histological indicator of the risk of malignancy [3,4]. The presence of both epithelial architectural disturbance and cytological atypia is required to define dysplasia, which is generally classified as mild, moderate and severe according to thickness of involvement of the epithelium [3]. However, rather than separate stages, the histologic changes represent a gamut of molecular and cytologic changes within the epithelial layers of oral mucosa, which can either progress or regress in time [3].

A premalignant condition/lesion has been defined as "the histopathologic changes seen in a chronic, progressive, and premalignant disorder of oral mucosa which may present itself clinically as leukoplakia, erythroplakia, or leukoerythroplakia, or may also be seen in verrucous or papillary leukoplakias, in the margins of a chronic mucosal ulcers, or in the adjacent mucosa of invasive squamous cell carcinoma" [5]. This term also refers to unpredictable diversity of risk and variable biology and pathogenesis of potential precursor lesions to cancer [6]. However, it is also noted that the severity of dysplasia within a potentially premalignant lesion/condition may imply the malignant potential of that particular lesion rather than the clinical presentation [4,5,7]. Thus, it may be suggested that oral potentially premalignant lesions/conditions can be better understood as the clinical manifestations of various degrees of oral mucosal epithelial dysplasia either at the molecular or histological level, resulting from the alterations of the epithelium and the cellular microenvironment (oral surface and microbiology and connective tissue) and immune function [8].

Discussion

The process of carcinogenesis is a broad and multi-dimensional process than the changes in the epithelial cells. This statement is included in discussions regarding the role of dysplasia and risk of progression to cancer; as some reports describe a risk of progression to cancer that is unrelated to the severity of dysplasia [9–12], while others revealed that the degree of dysplasia is associated with a risk of progression [5,13–15]. Unexpected transformation may be attributable to the unreliable nature of histological grading of epithelial dysplasia [10,16], or to the presence of invasion which may occur without any histological evidence of prior full-thickness change in the overlying epithelium [10]. Additionally, malignant transformation of a dysplastic lesion may have many other important components, including host dependent or behavioral factors and genetics [17–19], tobacco and alcohol consumption [20–22], inflammatory conditions [23,24], microbial factors [25–28], systemic disorders or medication use which in turn alter the cellular metabolism and immunosurveillance of the host [29,30], oral hygiene status [31,32] and nutritional conditions [31,33]. All these components may contribute to the development of malignant changes within and around an epithelial cell; thus, connective tissue signaling and immunosurveillance (related to either innate or adaptive immunity) are increasingly recognized as critical in pathogenesis [8]

* Corresponding author.
E-mail address: ilhanbetul@yahoo.com (B. Ilhan).

https://doi.org/10.1016/j.oraloncology.2019.03.009
Received 5 March 2019; Accepted 13 March 2019
Available online 25 March 2019

and potentially in management. Considering the complex and unpredictable nature of the transformation of oral epithelial cells from normal to malignant and the absence of a single etiological entity responsible for this alteration, today may be the time to discuss "'whether patients instead of lesions should be defined as having a potentially premalignant condition". This discussion would not only assist to clarify the actual status of a patient, but also help to determine the approaches to management [10,12,22,32,34–39]. The appropriate treatment is usually determined by both the lesion related factors such as the degree of dysplasia, location and size [10,12,34], and the patient related factors such as the age [12], general health status [36,37], oral conditions [32,35], and anticipated compliance of the patient to follow-up. However, as malignant transformation may also occur in non-dysplastic or low-grade lesions [12], all lesions require follow-up and the search for effective prevention and intervention is needed.

Considering that the immune function and tissue microenvironment and general health of the patient including habits and nutritional assessment play critical roles in pathogenesis and response to treatment, it may be time to address the conventional attitude towards prediction of malignant transformation of a lesion in oral cavity and analyze the patient as a whole, including genetic, endocrine, psychological, nutritional and oral aspects which are patient specific. A patient with a history of malignancy in the family, consumption of tobacco and alcohol, poor oral hygiene, various systemic diseases, having high level of stress and inadequate nutrition may be considered as a "high risk patient" and may deserve a thorough examination, including evaluation of some established biomarkers for malignant transformation of oral mucosal lesions (eg. EGFR, mTOR, LOH) and continuing clinical follow up. In this case, mild dysplasia identified in a "high-risk patient" may be treated with more aggressive treatment approaches and follow up than an analogue lesion noted in a "low risk patient". The potential for new interventions based upon molecular change and tumor microenvironment in addition to current approaches directed primarily to the epithelial changes may change future management of the premalignant patient.

Conclusion

Consideration of the patient's genetic, general, emotional and behavioral health components, and integration of tissue changes, microenvironment, proteomics, and growth factors and inflammatory biomarkers into this judgement process would eventually lead to "patient-unique treatment decision" which may impact management approach of potentially premalignant and malignant patient.

Conflict of interests

None declared.

References

[1] Zhang X, Han S, Han HY, Ryu MH, Kim KY, Choi EJ, et al. Risk prediction for malignant conversion of oral epithelial dysplasia by hypoxia related protein expression. Pathology 2013;45:478–83.

[2] Liao CT, Wallace CG, Lee LY, Hsueh C, Lin CY, Fan KH, et al. Clinical evidence of field cancerization in patients with oral cavity cancer in a betel quid chewing area. Oral Oncol 2014;50:721–31.

[3] Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 2008;7:127–33.

[4] Dionne KR, Warnakulasuriya S, Zain RB, Cheong SC. Potentially malignant disorders of the oral cavity: current practice and future directions in the clinic and laboratory. Int J Cancer 2015;136:503–15.

[5] Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:321–9.

[6] Van der Waal I. Oral potentially malignant disorders: is malignant transformation predictable and preventable? Med Oral Patol Oral Cir Bucal 2014;19:e386–90.

[7] Van der Waal I, Schepman KP, Van der Meij EH, Smeele LE. Oral leukoplakia: a clinicopathological review. Eur J Cancer B Oral Oncol 1997;33:291–301.

[8] Raj AT, Kheur S, Gupta AA, Patil VR, Kharat A. The need for combination immunotherapy in oncology. Oral Oncol. 2019. https://doi.org/10.1016/j.oraloncology.2019.02.013. Feb 18. pii: S1368-8375(19)30049-1.

[9] Holmstrup PP, Vedtofte PP, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol 2006;42:461–74.

[10] Edwards PC. The natural history of oral epithelial dysplasia: perspective on Dost et al. Oral Surg Oral Med Oral Pathol Oral Radiol 2014;117:263–6.

[11] Mogedas-Vegara A, Hueto-Madrid JA, Chimenos-Küstner E, Bescós-Atín C. The treatment of oral leukoplakia with the CO2 laser: A retrospective study of 65 patients. J Craniomaxillofac Surg 2015;43:677–81.

[12] Speight PM, Khurram SA, Kujan O. Oral potentially malignant disorders: risk of progression to malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol 2018;125:612–27.

[13] Bouquot JE, Speight PM, Farthing PM. Epithelial dysplasia of the oral mucosa-Diagnostic problems and prognostic features. Current Diagnostic Pathology 2006;12:11–21.

[14] Kumar A, Cascarini L, McCaul JA, Kerawala CJ, Coombes D, Godden D, et al. How should we manage oral leukoplakia? Br J Oral Maxillofac Surg 2013;51:377–83.

[15] Wang YY, Tail YH, Wang WC, Chen CY, Kao YH, Chen YK, et al. Malignant transformation in 5071 southern Taiwanese patients with potentially malignant oral mucosal disorders. BMC Oral Health 2014;5(14):99.

[16] Holmstrup PP, Vedtofte PP, Reibel J, Stoltze K. Oral premalignant lesions: is a biopsy reliable? J Oral Pathol Med 2007;36:262–6.

[17] Garnis C, Chari R, Buys TP, Zhang L, Ng RT, Rosin MP, et al. Genomic imbalances in precancerous tissues signal oral cancer risk. Mol Cancer 2009;23(8):50.

[18] Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncol 2009;45:301–8.

[19] Zhang L, Poh CF, Williams M, Laronde DM, Berean K, Gardner PJ, et al. Loss of heterozygosity (LOH) profiles-validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) 2012;5:1081–9.

[20] Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007;99:777–89.

[21] Brocklehurst P, Kujan O, Glenny AM, Oliver R, Sloan P, Ogden G et al. Screening programmes for the early detection and prevention of oral cancer. Cochrane Database of Systematic Reviews 2010, Issue 11. Art. No.: CD004150.

[22] Mello FW, Miguel AFP, Dutra KL, Porporatti AL, Warnakulasuriya S, Guerra ENS, et al. Prevalence of oral potentially malignant disorders: a systematic review and meta-analysis. J Oral Pathol Med 2018;47:633–40.

[23] Sun Y, Liu N, Guan X, Wu H, Sun Z, Zeng H. Immunosuppression Induced by Chronic Inflammation and the Progression to Oral Squamous Cell Carcinoma. Mediators Inflamm 2016;2016:5715719.

[24] Sano Y, Kogashiwa Y, Araki R, Enoki Y, Ikeda T, Yoda T, et al. Correlation of inflammatory markers, survival, and COX2 expression in oral cancer and implications for prognosis. Otolaryngol Head Neck Surg 2018;1. 194599817745284.

[25] Gorsky M, Epstein JB. Oral lichen planus: malignant transformation and human papilloma virus: a review of potential clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:461–4.

[26] Alnuaimi AD, Ramdzan AN, Wiesenfeld D, O'Brien-Simpson NM, Kolev SD, Reynolds EC, et al. Candida virulence and ethanol-derived acetaldehyde production in oral cancer and non-cancer subjects. Oral Dis 2016;22:805–14.

[27] Grønhøj C, Jakobsen KK, Jensen DH, Rasmussen J, Andersen E, Friborg J, et al. Pattern of and survival following loco-regional and distant recurrence in patients with HPV+ and HPV- oropharyngeal squamous cell carcinoma: a population-based study. Oral Oncol 2018;83:127–33.

[28] Khanal S, Shumway BS, Zahin M, Redman RA, Strickley JD, Trainor PJ, et al. Viral DNA integration and methylation of human papillomavirus type 16 in high-grade oral epithelial dysplasia and head and neck squamous cell carcinoma. Oncotarget 2018;9:30419–33.

[29] Hirai H, Tomioka H, Mochizuki Y, Oikawa Y, Tsushima F, Harada H. Clinical course of oral squamous cell carcinoma in patients on immunosuppressant and glucocorticoid therapy. J Oral Maxillofac Surg 2017;75:1980–6.

[30] Zamoiski RD, Yanik E, Gibson TM, Cahoon EK, Madeleine MM, Lynch CF, et al. Risk of second malignancies in solid organ transplant recipients who develop keratinocyte cancers. Cancer Res 2017;77:4196–203.

[31] Güneri P, Cankaya H, Yavuzer A, Güneri EA, Erişen L, Ozkul D, et al. Primary oral cancer in a Turkish population sample: association with sociodemographic features, smoking, alcohol, diet and dentition. Oral Oncol 2005;41:1005–12.

[32] Rosenquist K, Wennerberg J, Schildt EB, Bladström A. Göran Hansson B, Andersson G. Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta Otolaryngol 2005;125:1327–36.

[33] Chainani-Wu N, Epstein J, Touger-Decker R. Diet and prevention of oral cancer: strategies for clinical practice. J Am Dent Assoc 2011 Feb;142:166–9.

[34] Epstein JB, Gorsky M, Fischer D, Gupta A, Epstein M, Elad S. A survey of the current approaches to diagnosis and management of oral premalignant lesions. J Am Dent Assoc 2007;138:1555–62.

[35] Divaris K, Olshan AF, Smith J, Bell ME, Weissler MC, Funkhouser WK, et al. Oral health and risk for head and neck squamous cell carcinoma: the Carolina Head and Neck Cancer Study. Cancer Causes Control 2010;21:567–75.

[36] Tseng KS, Lin C, Lin YS, Weng SF. Risk of head and neck cancer in patients with diabetes mellitus: a retrospective cohort study in Taiwan. JAMA Otolaryngol Head Neck Surg 2014;140:746–53.

[37] Gong Y, Wei B, Yu L, Pan W. Type 2 diabetes mellitus and risk of oral cancer and precancerous lesions: a meta-analysis of observational studies. Oral Oncol 2015;51:332–40.

[38] Cromwell I, Regier DA, Peacock SJ, Poh CF. Cost-effectiveness analysis of using loss of heterozygosity to manage premalignant oral dysplasia in British Columbia, Canada. Oncologist 2016;21:1099–106.

[39] Zhang L, Lubpairee T, Laronde DM, Rosin MP. Should severe epithelial dysplasia be treated? Oral Oncol 2016;60:125–9.